Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme and Merck agree cancer assay licence:

This article was originally published in Clinica

Executive Summary

Genzyme Molecular Oncology has licensed non-exclusive rights to Merck for Genzyme's methods of assaying small molecule compounds for their action against the cancer-related protein, MDM2. Merck will pay up to $8 million in milestone payments if it can develop a therapeutic product through use of this assay.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT080485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel